Core Insights - The company has successfully won a bid for multiple AI capability platform projects with Beijing Friendship Hospital, marking significant progress in the smart healthcare sector [1][2] - The project utilizes the company's self-developed medical large model and core technologies for multi-modal data recognition and governance, establishing an intelligent service platform for the hospital [1] - The implementation of this platform has led to substantial improvements in data value extraction and diagnostic efficiency, with specific examples including an 80% increase in medical record entry efficiency and a 15% reduction in consultation time [1] Industry Developments - This initiative aligns with national policies promoting AI empowerment in healthcare, transitioning smart healthcare from single-scenario intelligence to comprehensive digital solutions across the entire diagnosis and treatment process [2] - The company has reinforced its leading position in the healthcare intelligence competition, leveraging its advanced medical capabilities demonstrated in authoritative evaluations like MedBench and its experience with over 30% of top-tier hospitals nationwide [2]

Core Insights - The company, Yunzhisheng (09678), has successfully won a bid for multiple AI capability platform projects with Beijing Friendship Hospital, marking a significant advancement in its smart healthcare technology and commercial application [1] Group 1: Project Details - The project utilizes the company's self-developed medical large model, multimodal data recognition and governance, and text reasoning technologies to create an intelligent service platform that hospitals can operate independently [1] - The platform integrates the hospital's knowledge base to form a specialized medical large model, breaking through traditional medical information construction models [1] Group 2: Operational Efficiency - The company has achieved unified management of multiple models and intelligent integration with business systems, significantly enhancing data value extraction and diagnostic efficiency in various scenarios such as wound image recognition, infection risk assessment, intelligent medical record generation, and follow-up management [1] - For instance, the outpatient medical record generation system at Beijing Friendship Hospital improved record entry efficiency by 80% and reduced consultation time by 15%, leading to a substantial increase in patient satisfaction [1] Group 3: Strategic Alignment - This project aligns with national policies promoting AI empowerment in healthcare, facilitating the transition from single-scenario intelligence to comprehensive digital solutions across the entire diagnostic and treatment process [1] - The company consolidates its leading position in healthcare intelligence competition, leveraging its advanced medical capabilities demonstrated in authoritative evaluations like MedBench and its experience covering over 30% of top-tier hospitals nationwide [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 最新業務進展 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新業務發展情況。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 自願性公告 於本公告日期，本公司董事會包括：(i)執行董事梁家恩博士、黃偉博士、康恒博士、李霄寒先生、劉升平先生及 李鵬先生；(ii)非執行董事鄺子平先生、李志超先生、汪存富先生及李昂先生；及(iii)獨立非執行董事胡建軍先生、 樊健先生、金慧華女士、張坤博士及陳華先生。 本公司董事會（「董事會」）欣然宣佈，本公司成功中標首都醫科大學北京友誼醫院（「北 京友誼醫院」）AI能力平台等多個智能體（Agent）項目，實現與北京友誼醫院在目前合作 基礎上服務關係的進一步深化，也標誌著本公司在智慧醫療領域的技術落地和商業 ...

Core Insights - OpenAI has launched GPT-5Pro and GPT-realtime-mini, emphasizing the trend towards lightweight and efficient AI models with strong multimodal interaction capabilities [1] - CloudWalk (云知声) has established itself as a significant player in the AI industry, leveraging its "chip-cloud integration" strategy and technological expertise [1] Group 1: Technological Advancements - CloudWalk's 0.5B parameter edge-side voice model, based on the Shanhai model distillation technology, is now operational in mass-produced vehicles from companies like Geely and Zhiji, demonstrating reduced hardware requirements and a response speed as low as 350ms [2] - The company has developed a comprehensive technology architecture consisting of "general large models - industry large models - edge-side lightweight models," which has earned it dual recognition with the "2025 AIEra Enterprise Innovation Award" and the "X Future Business Brand" award [2] Group 2: Financial Performance - In the first half of 2025, CloudWalk reported a 457% year-on-year increase in revenue from large model-related businesses, surpassing 100 million RMB, which now accounts for 24.4% of total revenue [3] - The edge-side voice model has established a presence across four major sectors: automotive, healthcare, transportation, and government, serving tens of millions of terminal devices [3] Group 3: Global Expansion - CloudWalk has partnered with the Nanning Municipal Government to establish an "ASEAN Headquarters Project," integrating edge-side voice models into Southeast Asia's transportation and cross-border healthcare scenarios [4] - The launch of GPT-5Pro validates the market potential for small voice models, while CloudWalk is proactively pursuing both localization and globalization strategies [4] - The company's technological approach reflects the innovative logic of Chinese AI enterprises, focusing on full-stack technical capabilities and differentiated competition through "large model technology downscaling and deep scene adaptation" [4]

Core Insights - Cloud Wisdom, known as the "first AGI stock in Hong Kong," successfully listed on the Hong Kong Stock Exchange on June 30, 2025, and was included in the Hang Seng Composite Index in September, indicating strong market recognition of its value [1] - The company reported a revenue of 405 million yuan in the first half of 2025, a year-on-year increase of 20.2%, with revenue from large model-related businesses surging by 457.4% to 98.76 million yuan, accounting for nearly 25% of total revenue [1] - The launch of OpenAI's Sora2 has revolutionized the AI video generation industry, aligning with Cloud Wisdom's strategic direction in multi-modal technology [2] Financial Performance - In the first half of 2025, Cloud Wisdom achieved a revenue of 405 million yuan, reflecting a 20.2% year-on-year growth [1] - Revenue from large model-related businesses increased by 457.4% to 98.76 million yuan, highlighting the effectiveness of its technology commercialization [1] - The company is expected to achieve a compound annual growth rate of 25% in revenue from 2022 to 2024, with a focus on long-term growth over short-term profitability [4] Technological Advancements - Cloud Wisdom's "Cloud Brain" integrates multi-modal perception and generation, knowledge graphs, and IoT platforms, achieving high performance and low latency in edge deployment [2] - The company's medical industry-specific large model, UniGPT-Med-U1, ranked first in the MedBench evaluation, showcasing its capability to integrate medical imaging, clinical texts, and voice diagnostic data [3] - The combination of Cloud Wisdom's existing voice interaction system with Sora2's scene generation technology can enhance user experience in smart cockpit scenarios [3] Strategic Positioning - The release of the "AI+" policy by the State Council provides clear guidance for the integration of AI technology with various industries, aligning with Cloud Wisdom's business layout [3] - The company is pursuing a dual strategy of deepening domestic market presence while expanding internationally, evidenced by partnerships with the Guangxi Health Commission and the Vanuatu government [3] - Cloud Wisdom's approach of "investing in R&D for growth" aims to build long-term competitiveness, with a focus on achieving a profitability inflection point as multi-modal technology commercializes [4] Market Outlook - The market recognizes Cloud Wisdom's long-term potential as a leader in the AGI era, with a current market valuation of 60 billion HKD [4] - The company's unique barriers formed by its technological reserves and industry know-how position it favorably for future growth [4] - The combination of policy support and international expansion opens new market opportunities for Cloud Wisdom [4][5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 雲知聲智能科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09678 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 41,621,883 | RMB | | 1 RMB | | 41,621,883 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 41,621,883 | RMB | | 1 RMB | | 41,621,883 | | 2. 股份分類 ...

UNISOUND AI TECHNOLOGY CO., LTD. （股份代號：9678） 2025 年 1 0 月 1 7 日(星期五)舉行的 2025 年第二次臨時股東大會之股東代表委任表格 本委任表格代表的 股份數目 （附註1） 本人╱吾等 （附註2） | | 特別決議案 | （附註5） 贊成 | （附註5） 反對 | （附註5） 棄權 | | --- | --- | --- | --- | --- | | 1. | 審議及批准關於取消監事會、修訂《公司章程》及其附件並辦理工商 | | | | | | 變更登記的議案： | | | | | | 1.1 審議及批准關於取消監事會的議案。 | | | | | | 1.2 審議及批准關於修訂《公司章程》並辦理工商變更登記的議案。 | | | | | | 1.3 審議及批准關於修訂《股東會議事規則》的議案。 | | | | | | 1.4 審議及批准關於修訂《董事會議事規則》的議案。 | | | | | | 普通決議案 | （附註5） 贊成 | （附註5） 反對 | （附註5） 棄權 | | 2. | 審議及批准關於公司2024年度董事會工作報告的議案。 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 2025 年第二次臨時股東大會通告 茲通告雲知聲智能科技股份有限公司（「本公司」）謹訂於2025年10月17日（星期五）上午10 時正於雲知聲智能科技股份有限公司二層會議室（中國北京市海淀區建材城中路27號金隅 智造工場N6號樓）以現場會議形式召開2025年第二次臨時股東大會（「臨時股東大會」）， 以審議並酌情通過下列決議案： 特別決議案 1. 審議及批准關於取消監事會、修訂《公司章程》及其附件並辦理工商變更登記的議 案。 普通決議案 1 2. 審議及批准關於公司2024年度董事會工作報告的議案。 3. 審議及批准關於公司2024年度獨立非執行董事工作報告的議案。 4. 審議及批准關於公司2024年度財務決算報告的議案。 5. 審議及批准關於續聘 ...

此乃要件 請即處理 閣下如對本通函任何方面有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券商、銀行 經理、律師、專業會計師或其他專業顧問。 閣下如已將名下之雲知聲智能科技股份有限公司股份全部售出或轉讓，應立即將本通函及隨 附的代表委任表格交予買主或承讓人或經手買賣或轉讓之銀行、股票經紀或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 關 於 取 消 監 事 會 、修 訂《 公 司 章 程 》及 其附件並辦理工商變更登記的議案 關於公司 2024 年度董事會工作報告的議案 關於公司 2024 年度獨立非執行董事工作報告的議案 關於公司 2024 年度財務決算報告的議案 關於續聘 2025 年度審計機構的議案 關於公司 2024 年度利潤分配方案的議案 關於 ...

Core Viewpoint - The article discusses the recent adjustments in the Hong Kong Stock Connect market, highlighting the rapid inclusion of new stocks and the associated risks of price volatility and market manipulation. Group 1: Market Adjustments - As of September 2025, a total of 67 stocks were included in the Hong Kong Stock Connect, while 61 were removed, indicating a significant turnover in the market [1] - New stocks listed for less than six months can quickly enter the market if they meet liquidity and market capitalization requirements, raising concerns about the adequacy of their assessment periods [1][4] Group 2: Inclusion Rules - The general rules for inclusion in the Hong Kong Stock Connect require that stocks achieve a daily average market capitalization covering the top 95% of the Hong Kong market and pass liquidity tests [1][2] - Stocks can be included in the Hang Seng Composite Index and the Stock Connect simultaneously if they meet the criteria during specific review periods [2] Group 3: Case Studies of New Stocks - iFlytek Medical Technology was listed on December 30, 2024, and included in the Stock Connect on March 10, 2025, after only 70 days, with an average market capitalization of HKD 6.8 billion [6] - The stock experienced a 72% price increase due to speculative trading before its inclusion, but subsequently fell nearly 40% within a month after the initial hype faded [7] - Health Road, listed and included on the same day as iFlytek, also faced a significant drop in stock price post-inclusion, highlighting the lack of sustainable trading activity [8][9] Group 4: Market Manipulation Risks - The rapid inclusion of stocks like iFlytek and Health Road has exposed vulnerabilities in the Stock Connect assessment mechanism, where stocks can be manipulated for short-term gains [4][6] - Cloud Wisdom, which was listed on June 30, 2025, saw its stock price rise significantly on its first day, but later faced a sharp decline due to poor financial performance and lack of institutional support [11][13]